Study S000009

A Pilot Study of Exendin-4 in Alzheimer s Disease

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01255163
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: TERMINATED
Enrollment: 57
Start: 2010-11-21
Primary completion: 2016-11-18
Lead sponsor: National Institute on Aging (NIA)
Conditions: Alzheimer's Disease; Mild Cognitive Impairment
Interventions: DRUG:Exendin-4 SC; DRUG:Placebo SC
Results posted: TRUE
Secondary identifiers: OTHER:10-AG-0423

Registered primary outcomes

Number of Participants With Incidence of Nausea [18 months]

Linked records (4)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0020471	A Pilot Study of Exenatide Actions in Alzheimer's Disease. Mullins RJ, Current Alzheimer research	2019	Randomized trial	PMID 31518224 DOI	cites ClinicalTrials.gov:NCT01255163; registry reference DERIVED:31518224
R0018678	Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes. Muscogiuri G, Trends in endocrinology and metabolism: TEM	2017	Narrative review	PMID 27871675 DOI	cites ClinicalTrials.gov:NCT01255163; registry reference DERIVED:27871675
R0055022	Glucagon peptide-like 1 receptor (GLP-1R) expression per se: a new insight into neurodegenerative disease? Soo-hyun Park, Neural Regeneration Research	2015	Other trial	PMID 26330822 DOI	cites ClinicalTrials.gov:NCT01255163
R0023266	An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers. Bomfim TR, The Journal of clinical investigation	2012	Preclinical	PMID 22476196 DOI	registry reference BACKGROUND:22476196